LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
In a current clinical trial, NAC is being used to protect PD patients from oxidative damage (161)
Results NAC catabolism induces rapid oxidation of mitochondrial, but not cytosolic, roGFP2 Motivated by our earlier Drosophila experiments (Albrecht et al., 2011), we started out by asking if NAC treatment would induce oxidation of the genetically encoded redox probe roGFP2 in cultured human cells
[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Boullata J.I
Neuroprotective and anticonvulsant effects of sinomenine in kainate rat model of temporal lobe epilepsy: involvement of oxidative stress, inflammation and pyroptosis